Alzheimer’s disease is largely the underlying cause of dementia due to its progressive neurodegenerative nature among the elderly. The disease can be divided into five stages: Subjective Memory Concern (SMC), Mild Cognitive Impairment (MCI), Early MCI (EMCI), Late MCI (LMCI), and Alzheimer’s Disease (AD). Alzheimer’s disease is conventionally diagnosed using an MRI scan of the brain. In this research, we propose a fine-tuned convolutional neural network (CNN) classifier called AlzheimerNet, which can identify all five stages of Alzheimer’s disease and the Normal Control (NC) class. The ADNI database’s MRI scan dataset is obtained for use in training and testing the proposed model. To prepare the raw data for analysis, we applied the CLAHE image enhancement method. Data augmentation was used to remedy the unbalanced nature of the dataset and the resultant dataset consisted of 60000 image data on the 6 classes. Initially, five existing models including VGG16, MobileNetV2, AlexNet, ResNet50 and InceptionV3 were trained and tested to achieve test accuracies of 78.84%, 86.85%, 78.87%, 80.98% and 96.31% respectively. Since InceptionV3 provides the highest accuracy, this model is later modified to design the AlzheimerNet using RMSprop optimizer and learning rate 0.00001 to achieve the highest test accuracy of 98.67%. The five pre-trained models and the proposed fine-tuned model were compared in terms of various performance matrices to demonstrate whether the AlzheimerNet model is in fact performing better in classifying and detecting the six classes. An ablation study shows the hyperparameters used in the experiment. The suggested model outperforms the traditional methods for classifying Alzheimer’s disease stages from brain MRI, as measured by a two-tailed Wilcoxon signed-rank test, with a significance of < 0.05.

COVID-19, regarded as the deadliest virus of the 21st century, has claimed the lives of millions of people around the globe in less than two years. Since the virus initially affects the lungs of patients, X-ray imaging of the chest is helpful for effective diagnosis. Any method for automatic, reliable, and accurate screening of COVID-19 infection would be beneficial for rapid detection and reducing medical or healthcare professional exposure to the virus. In the past, Convolutional Neural Networks (CNNs) proved to be quite successful in the classification of medical images. In this study, an automatic deep learning classification method for detecting COVID-19 from chest X-ray images is suggested using a CNN. A dataset consisting of 3616 COVID-19 chest X-ray images and 10,192 healthy chest X-ray images was used. The original data were then augmented to increase the data sample to 26,000 COVID-19 and 26,000 healthy X-ray images. The dataset was enhanced using histogram equalization, spectrum, grays, cyan and normalized with NCLAHE before being applied to CNN models. Initially using the dataset, the symptoms of COVID-19 were detected by employing eleven existing CNN models; VGG16, VGG19, MobileNetV2, InceptionV3, NFNet, ResNet50, ResNet101, DenseNet, EfficientNetB7, AlexNet, and GoogLeNet. From the models, MobileNetV2 was selected for further modification to obtain a higher accuracy of COVID-19 detection. Performance evaluation of the models was demonstrated using a confusion matrix. It was observed that the modified MobileNetV2 model proposed in the study gave the highest accuracy of 98% in classifying COVID-19 and healthy chest X-rays among all the implemented CNN models. The second-best performance was achieved from the pre-trained MobileNetV2 with an accuracy of 97%, followed by VGG19 and ResNet101 with 95% accuracy for both the models. The study compares the compilation time of the models. The proposed model required the least compilation time with 2 h, 50 min and 21 s. Finally, the Wilcoxon signed-rank test was performed to test the statistical significance. The results suggest that the proposed method can efficiently identify the symptoms of infection from chest X-ray images better than existing methods.

The incidence of chronic kidney disease (CKD) is rising rapidly around the globe. Asymptomatic CKD is common and guideline-directed monitoring to predict CKD by various factors is underutilized. Computer-aided automated diagnostic (CAD) can play a major role to predict CKD. CAD systems such as deep learning algorithms are pivotal in disease diagnosis due to their high classification accuracy. In this paper, various clinical features of CKD were utilized and seven state-of-the-art deep learning algorithms (ANN, LSTM, GRU, Bidirectional LSTM, Bidirectional GRU, MLP, and Simple RNN) were implemented for the prediction and classification of CKD. The proposed algorithms were applied based on artificial intelligence by extracting and evaluating features using five different approaches from pre-processed and fitted CKD datasets. In this study, we have measured accuracy, precision, recall, and calculated the loss and validation loss in prediction. Further, the study analyzed computation time and prediction ratio, and AUC to evaluate the model performance along with statistical significance to compare their performances. While classifying CKD, algorithms such as ANN, Simple RNN, and MLP provided high accuracy of 99%, 96%, and 97% respectively., a good prediction ratio along reduced time. The model outperforms traditional data classification techniques by providing superior predictive ability. Subsequently, the study proposed the integration of best-performing DL models in the IoMT. This proposal will assist predictive analytics to advance CKD prediction by using deep learning more efficiently and effectively. The study is the first fundamental step toward a comprehensive performance assessment to classify and predict CKD using deep learning models and its associated risk factors.

In humans, the dimeric receptor complex IFNAR2-IFNAR1 accelerates cellular response triggered by type I interferon (IFN) family proteins in response to viral infection including Coronavirus infection. Studies have revealed the association of the IFNAR2 gene with severe illness in Coronavirus infection and indicated the association of genomic variants, i.e. single nucleotide polymorphisms (SNPs). However, comprehensive analysis of SNPs of the IFNAR2 gene has not been performed in both coding and non-coding region to find the causes of loss of function of IFNAR2 in COVID-19 patients. In this study, we have characterized coding SNPs (nsSNPs) of IFNAR2 gene using different bioinformatics tools and identified deleterious SNPs. We found 9 nsSNPs as pathogenic and disease-causing along with a decrease in protein stability. We employed molecular docking analysis that showed 5 nsSNPs to decrease binding affinity to IFN. Later, MD simulations showed that P136R mutant may destabilize crucial binding with the IFN molecule in response to COVID-19. Thus, P136R is likely to have a high impact on disrupting the structure of the IFNAR2 protein. GTEx portal analysis predicted 14 sQTLs and 5 eQTLs SNPs in lung tissues hampering the post-transcriptional modification (splicing) and altering the expression of the IFNAR2 gene. sQTLs and eQTLs SNPs potentially explain the reduced IFNAR2 production leading to severe diseases. These mutants in the coding and non-coding region of the IFNAR2 gene can help to recognize severe illness due to COVID 19 and consequently assist to develop an effective drug against the infection. Communicated by Ramaswamy H. Sarma